Barclays PLC Has $973,000 Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Barclays PLC grew its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1,316.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,113 shares of the company’s stock after purchasing an additional 130,219 shares during the quarter. Barclays PLC’s holdings in GoodRx were worth $973,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rubric Capital Management LP grew its position in GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after buying an additional 943,226 shares in the last quarter. Millennium Management LLC grew its position in GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after buying an additional 1,102,758 shares in the last quarter. American Century Companies Inc. acquired a new stake in GoodRx during the second quarter worth approximately $18,183,000. Point72 Asset Management L.P. acquired a new stake in GoodRx during the third quarter worth approximately $11,295,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Morgan Stanley cut their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Mizuho assumed coverage on GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Citigroup cut their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Finally, Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, GoodRx has an average rating of “Moderate Buy” and a consensus price target of $8.37.

GoodRx Stock Performance

Shares of GDRX opened at $4.51 on Tuesday. The company has a market cap of $1.72 billion, a PE ratio of -150.33, a P/E/G ratio of 3.54 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The stock has a 50-day moving average of $5.09 and a 200-day moving average of $6.81.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.